• NGT subjects will serve as controls and will be matched in age, gender, ethnicity, and BMI to IGT and IFG subjects

‣ Male or female subjects between the ages of 18 and 65 years of age, inclusive, at Screening.

⁃ FPG \< 100 mg/dl and 2-h PG \< 140 mg/dl

⁃ BMI = 24-40 kg/m2;

⁃ Stable body weight (±4lbs) over the preceding 3 months

⁃ Subjects with no evidence of major organ system disease as determined by physical exam, history, and screening laboratory data

⁃ Females of childbearing potential with a negative pregnancy test at Screening and Treatment visits, using one of the following forms of contraception for the duration of participation in the study (i.e., until Follow-up 7-14 days post last dose):

• Oral contraceptive

∙ Injectable progesterone

∙ Subdermal implant

∙ Spermicidal foam/gel/film/cream/suppository

∙ Diaphragm with spermicide

∙ Copper or hormonal containing IUD

∙ Sterile male partner vasectomized \> 6 month pre-dosing.

⁃ Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.

⁃ Subjects must be willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures.